April 30, 2026

Digital Twin Model May Improve Alcohol Intake Reconstruction

Integrated biomarker framework supports evaluation of drinking scenarios in forensic settings

Conexiant

April 30, 2026

Post-Dobbs Mortality Trends Remain Unclear

National cohort shows smaller mortality declines in ban states and divergent patterns by race and geography.

Conexiant

April 30, 2026

FDA Approves Auvelity for Agitation in Alzheimer’s Disease

The oral combination therapy expands treatment options for agitation associated with dementia due to Alzheimer’s disease.

Conexiant

April 30, 2026

SSc May Be Linked to Subtle Cognitive Changes

Cross-sectional study finds domain-specific differences and higher anxiety without global impairment.

Conexiant

April 30, 2026

Medical Oddities: From Romance to Recall Issues

Mental health check: what patients eat, watch, love, and dream may all be in play

Conexiant

April 30, 2026

Urgent Care, Unchecked Power

An unsupervised clinic model and blurred boundaries expose how oversight can fail in outpatient care.

Conexiant

April 29, 2026

FDA Updates Lumateperone Label With Relapse-Prevention Data

Label update incorporates randomized withdrawal trial findings showing delayed time to relapse and consistent safety profile in schizophrenia

Conexiant

April 29, 2026

FDA Monthly Preview: Key May Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Conexiant

April 29, 2026

PT vs CBT for Chronic Low Back Pain

Sequential, multiple-assignment randomized trial compares stage I and stage II nonpharmacologic treatments over 52 weeks.

Conexiant

April 29, 2026

Mass Spec Roundup: From Alzheimer’s to Antarctic Dust 

New studies highlight hidden molecular patterns in Alzheimer’s disease, dolphin milk, Antarctic dust, and oxidative DNA damage 

The Analytical Scientist